Fluconazole
Brand names: Diflucan, Fluconazole
At a glance
- Medicare prescriptions, 2024
- 2,286,644
- Medicare drug cost
- $23.9M
- Average cost per prescription
- $10.45
- Clinicians who prescribed it
- 96,253
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
DIFLUCAN (fluconazole) is indicated for the treatment of: 1. Vaginal candidiasis (vaginal yeast infections due to Candida ). 2. Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, DIFLUCAN was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. 3. Cryptococcal meningitis. Before prescribing DIFLUCAN (fluconazole) for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing DIFLUCAN to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis:
From the FDA-approved prescribing information (label dated April 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Nurse Practitioners 28.0%
- Family Medicine 25.6%
- Internal Medicine 15.7%
- Physician Assistants 8.8%
- OB-GYN (Obstetrics & Gynecology) 5.6%
- Dermatology 2.5%
- Urology 1.7%
- Infectious Disease 1.7%
- General Practice 1.3%
- Podiatrists 0.9%
- Nephrology (Kidney) 0.8%
- Pulmonology 0.7%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 23% from 2019 to 2024.
Biggest change by state since 2019
- Utah +37%
- Nevada +34%
- Minnesota +30%
- North Dakota +29%
- Mississippi +29%
- Puerto Rico (smallest change) +9%
- Oregon (smallest change) +9%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 4 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Coupler LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 100 mg | pink trapezoid tablet, 10 mm | 100 |
Roerig
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | pink trapezoid tablet, 8 mm | DIFLUCAN 50 ROERIG |
| 100 mg | pink trapezoid tablet, 10 mm | DIFLUCAN 100 ROERIG |
| 150 mg | pink oval tablet, 12 mm | DIFLUCAN 150 ROERIG |
| 200 mg | pink trapezoid tablet, 12 mm | DIFLUCAN 200 ROERIG |
Zydus Lifesciences Limited
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | pink oval tablet, 8 mm | 1137 |
| 100 mg | pink oval tablet, 10 mm | 1138 |
| 150 mg | pink oval tablet, 11 mm | 1139 |
| 200 mg | pink oval tablet, 12 mm | 1140 |
Zydus Pharmaceuticals (USA) Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | pink oval tablet, 8 mm | 1137 |
| 100 mg | pink oval tablet, 10 mm | 1138 |
| 150 mg | pink oval tablet, 11 mm | 1139 |
| 200 mg | pink oval tablet, 12 mm | 1140 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.